Columbia University researchers recently generated beating cardiac tissue from induced pluripotent stem cells, human cells that are able to differentiate into nearly any cell type. Using physical conditioning, the researchers produced samples with the hallmarks of mature heart tissue with just four weeks of cell culture. The work paves a concrete pathway to functional heart-on-a-chip platforms.
Columbia University engineers use a soft mesh scaffold to produce a dramatically higher amount of functional T cells from blood taken from leukemia patients.
Gain access to free tools and resources from AABME, an initiative designed to stimulate biomedical innovation by bringing together and providing resources to the biomedical engineering community.
Harvard professor George Church discusses advances in portable genome monitoring as well as recent developments in the anti-aging therapies for which is he is so well known.
Cellular Biomedicine Group, a clinical-stage biopharmaceutical company that develops immunotherapies for cancer and stem cell therapies for degenerative diseases, recently partnered with GE Healthcare to build a platform to produce therapies at scale for clinical trials. Aims to solve challenge of developing enough genetically modified cells to test products on large populations.
Lorenzo Moroni and his team at University of Maastricht's Institute for Technology-Inspired Regenerative Medicine (MERLN) in The Netherlands, use 3D bioprinting to create "smart scaffolds," which they seed with patient stem cells and growth factors to produce structures that behave like natural cartilage tissues.
Joseph Wu Director of the Stanford Cardiovascular Institute and Professor of Medicine and Radiology at Stanford University, discusses the rise of engineered cell and tissue products for use in patients. While these products are now technically advanced and better suited for the clinic, there continues to be issues around patient safety that need to be monitored and mitigated for routine use and mass production.
For the first time, the revolutionary gene-editing technology called CRISPR-Cas9 was used to repair a disease-causing genetic flaw in viable human embryos and prevent the mutation from being passed to future generations.
A new nuclease inhibitor drug program could lead to the commercialization of novel DNA damage response (DDR) treatments for female breast, ovarian, and other types of cancers.
Rice University researchers have found that breaking down a virus’s tough outer shell creates nanoparticles that could improve the delivery of chemotherapies and other medicines to diseased cells.
Dr. Patrick Hanley, assistant research professor of pediatrics in the Center for Cancer and Immunology research at the Children’s Research Institute in Washington D.C. and director of the Good Manufacturing Practices cell therapy laboratory at Children’s National Health System, on the new developments in the design and manufacturing for T cell therapies. He discussed ways in which technology can help simplify the methodologies and bring consistency and scalability to cell manufacturing.
Georgia Tech Engineers created an organization to develop standards and production processes designed to mass produce life-saving cell-based therapeutics at affordable prices. Via AABME.
A new ultrasound technique that manipulates immune cells from outside the body could be the future of cancer care.
Researchers discover new molecular linker that orients targeting antibodies to help nucleic-acid filled particles reach target cells via AABME
Testing drugs against patients’ cancer cells—without subjecting patients to chemotherapy—could lead to better, faster treatment.